Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy.
Pico de Coaña Y, Masucci G, Hansson J, Kiessling R. Pico de Coaña Y, et al. Among authors: hansson j. Cancer Immunol Immunother. 2014 Sep;63(9):977-83. doi: 10.1007/s00262-014-1570-7. Epub 2014 Jun 26. Cancer Immunol Immunother. 2014. PMID: 24966003 Free PMC article.
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.
Pico de Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, Masucci GV, Kiessling R. Pico de Coaña Y, et al. Among authors: hansson j. Cancer Immunol Res. 2013 Sep;1(3):158-62. doi: 10.1158/2326-6066.CIR-13-0016. Epub 2013 Aug 2. Cancer Immunol Res. 2013. PMID: 24777678 Clinical Trial.
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.
Poschke I, Lövgren T, Adamson L, Nyström M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R. Poschke I, et al. Among authors: hansson j. Cancer Immunol Immunother. 2014 Oct;63(10):1061-71. doi: 10.1007/s00262-014-1575-2. Epub 2014 Jul 4. Cancer Immunol Immunother. 2014. PMID: 24993563 Free PMC article. Clinical Trial.
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.
Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, Kiessling R. Johansson CC, et al. Among authors: hansson j. Cancer Immunol Immunother. 2009 Jul;58(7):1085-94. doi: 10.1007/s00262-008-0631-1. Epub 2008 Nov 28. Cancer Immunol Immunother. 2009. PMID: 19039588 Free PMC article.
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.
Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B, Kiessling R, Masucci GV. Helgadottir H, et al. Among authors: hansson j. Cancer Immunol Immunother. 2009 Oct;58(10):1599-608. doi: 10.1007/s00262-009-0669-8. Epub 2009 Feb 13. Cancer Immunol Immunother. 2009. PMID: 19214504 Free PMC article.
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, Hansson J, Kiessling R. de Coaña YP, et al. Among authors: hansson j. Oncotarget. 2017 Mar 28;8(13):21539-21553. doi: 10.18632/oncotarget.15368. Oncotarget. 2017. PMID: 28423487 Free PMC article. Clinical Trial.
471 results